Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene

Brain Res. 2001 Jul 6;906(1-2):13-24. doi: 10.1016/s0006-8993(01)02531-8.


Until recently the opioid receptor family was thought to consist of only the mu-, delta- and kappa-receptors. The cloning of opioid receptor like receptor (ORL1) and its endogenous ligand nociceptin/orphanin FQ, which displayed anti-opioid properties, has raised the issue of functional co-operativity of this system with the classical opioid system. ORL1 receptor knockout mice have been successfully developed by homologous recombination to allow the issue of potential heterogeneity of this receptor and also of compensatory changes in mu-, delta- or kappa-receptors in the absence of ORL1 to be addressed. We have carried out quantitative autoradiographic mapping of these receptors in the brains of mice that are wild-type, heterozygous and homozygous for the deletion of the ORL1 receptor. ORL1, mu-, delta- and kappa-receptors were labelled with [(3)H] leucyl-nociceptin (0.4 nM), [(3)H] DAMGO (4 nM), [(3)H] deltorphin-I (7 nM), and [(3)H] CI-977 (2.5 nM) respectively. An approximately 50% decrease in [(3)H] leucyl-nociceptin binding was seen in heterozygous ORL1 mutant mice and there was a complete absence of binding in homozygous brains indicating the single gene encodes for the ORL1 receptor and any putative subtypes. No significant gross changes in the binding to other opioid receptors were seen across genotypes in the ORL1 mutant mice demonstrating a lack of major compensation of classical opioid receptors in the absence of ORL1. There were a small number of region specific changes in the expression of classical opioid receptors that may relate to interdependent function with ORL1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analgesics, Opioid / pharmacology
  • Animals
  • Autoradiography
  • Benzofurans / pharmacology
  • Binding Sites / drug effects
  • Binding Sites / physiology
  • Brain / cytology
  • Brain / drug effects
  • Brain / metabolism*
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / pharmacokinetics
  • Gene Deletion
  • Mice
  • Mice, Knockout / genetics
  • Mice, Knockout / metabolism
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neuroprotective Agents / pharmacology
  • Oligopeptides / pharmacology
  • Opioid Peptides / pharmacokinetics
  • Pyrrolidines / pharmacology
  • Radioligand Assay
  • Receptors, Opioid / deficiency*
  • Receptors, Opioid / genetics
  • Receptors, Opioid, delta / drug effects
  • Receptors, Opioid, delta / metabolism*
  • Receptors, Opioid, kappa / drug effects
  • Receptors, Opioid, kappa / metabolism*
  • Receptors, Opioid, mu / drug effects
  • Receptors, Opioid, mu / metabolism*
  • Tritium / pharmacokinetics


  • Analgesics, Opioid
  • Benzofurans
  • Neuroprotective Agents
  • Oligopeptides
  • Opioid Peptides
  • Pyrrolidines
  • Receptors, Opioid
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • Tritium
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • deltorphin I, Ala(2)-
  • nociceptin
  • nociceptin receptor
  • enadoline